**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74665

**Manuscript Type:** CASE REPORT

**Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report**

Xu LQ *et al*. Successful treatment with osimertinib

Li-Qing Xu, Ying-Jin Wang, Sheng-Li Shen, Yao Wu, Hong-Zhou Duan

**Li-Qing Xu, Ying-Jin Wang, Sheng-Li Shen, Yao Wu, Hong-Zhou Duan,** Department of Neurosurgery, Peking University First Hospital, Beijing 100034, China

**Author contributions:** Xu LQ conceived the article; Xu LQ and Wang YJ collected the data; Wang YJ assembled the data; Xu LQ, Wang YJ, Shen SL, Wu Y and Duan HZ provided the study materials, write the manuscript and approved the manuscript.

**Corresponding author: Hong-Zhou Duan, Doctor, PhD, Chief Doctor,** Department of Neurosurgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. duanhongzhou@126.com

**Received:** February 11, 2022

**Revised:** June 2, 2022

**Accepted:** June 21, 2022

**Published online:** August 6, 2022

**Abstract**

BACKGROUND

Patients diagnosed with non-small-cell lung cancer with activated epidermal growth factor receptor mutations are more likely to develop leptomeningeal (LM) metastasis than other types of lung cancers and have a poor prognosis. Early diagnosis and effective treatment of leptomeningeal carcinoma can improve the prognosis.

CASE SUMMARY

A 55-year-old female with a progressive headache and vomiting for one month was admitted to Peking University First Hospital. She was diagnosed with lung adenocarcinoma with osseous metastasis 10 months prior to admittance. epidermal growth factor receptor (EGFR) mutation was detected by genomic examination, so she was first treated with gefitinib for 10 months before acquiring resistance. Cell-free cerebrospinal fluid (CSF) circulating tumor DNA detection by next-generation sequencing was conducted and indicated the EGFR-Thr790Met mutation, while biopsy and cytology from the patient’s CSF and the first enhanced cranial magnetic resonance imaging (MRI) showed no positive findings. A month later, the enhanced MRI showed linear leptomeningeal enhancement, and the cytology and biochemical examination in CSF remained negative. Therefore, osimertinib (80  mg/d) was initiated as a second-line treatment, resulting in a good response within a month.

CONCLUSION

This report suggests clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in CSF and proposes that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging and CSF findings and may thus be helpful for therapy. Moreover, the routine screening of chest CT with the novel coronavirus may provide unexpected benefits.

**Key Words:** Non-small cell lung cancer; Epidermal growth factor receptor mutation; Circulating tumor DNA detection; Leptomeningeal carcinomatosis; Osimertinib; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Xu LQ, Wang YJ, Shen SL, Wu Y, Duan HZ. Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report. *World J Clin Cases* 2022; 10(22): 7968-7972

**URL**: https://www.wjgnet.com/2307-8960/full/v10/i22/7968.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v10.i22.7968

**Core Tip:** Examination of circulating tumor DNA in cell-free cell-free cerebrospinal fluid (CSF) has been shown to be useful for detecting the genomic mutations of tumors in the central nervous system, and osimertinib is considered to be a recent standardized treatment for epidermal growth factor receptor (EGFR) Thr790Met-mutant non-small-cell lung cancer (NSCLC). Hence, we report a patient with EGFR Thr790Met-mutant NSCLC with meningeal carcinomatosis and resistance to gefitinib and propose that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations that may appear earlier than the imaging and CSF findings and thus be helpful for therapy.

**INTRODUCTION**

Patients diagnosed with non-small-cell lung cancer (NSCLC) with activated epidermal growth factor receptor (EGFR) mutations are more apt to develop leptomeningeal (LM) metastasis than other types of lung cancers[1]. According to previous studies, patients with NSCLC with LM carcinoma have a poor prognosis[2]. Early diagnosis and effective treatment of LM carcinoma can improve the prognosis. Circulating tumor DNA (ctDNA) is composed of short, double-stranded DNA fragments from tumor cells. Examination of ctDNA in cell-free cerebrospinal fluid (CSF) has been shown to be useful in detecting the genomic mutations of tumors in the central nervous system (CNS) and has also been used to monitor tumor progression and evaluate the response to treatments[3-5]. However, it is unclear whether ctDNA detection in CSF can provide valuable clinical guidance for the treatment of meningeal metastases. Molecular targeted drugs such as EGFR tyrosine kinase inhibitors (TKIs) have been shown to be effective for patients with NSCLC and LM carcinoma who carry target oncogenes[6]. Osimertinib, a third-generation EGFR TKI, is considered to be a recent standardized treatment for EGFR Thr790Met-mutant NSCLC because of its good efficacy in both systemic and CNS metastasis[7]. However, relevant information about the effectiveness of osimertinib in EGFR Thr790Met-mutant meningeal carcinomatosis is limited. Here, we report a case of patient with EGFR Thr790Met-mutant NSCLC with meningeal carcinomatosis, which is resistant to gefitinib.

**CASE PRESENTATION**

***Chief complaints***

A 55-year-old female experiencing a progressive headache and vomiting for one month was admitted to our hospital.

***History of present illness***

 55-year-old female experiencing a progressive headache and vomiting for one month was admitted to our hospital. She was diagnosed with lung adenocarcinoma (Figure 1A) with osseous metastasis 10 mo prior to admittance. EGFR mutation was detected upon genomic examination, so she was first treated with gefitinib for 10 mo before acquiring resistance. A previous enhanced cerebral magnetic resonance imaging (MRI) and PET-CT one month prior showed that there was no obvious abnormality in the CNS. Lumbar puncture showed an increased intracranial pressure (+ACY-gt+ADs-330 mmH2O) without positive cytology and biochemical examination findings in the CSF. However, further CSF ctDNA detection by next-generation sequencing showed an EGFR-Thr790Met mutation. After the patient was admitted, a second enhanced MRI was performed and showed comprehensive linear leptomeningeal enhancement in the cerebral sulcus (Figure 1B). A second cytology and biochemical examination of the CSF remained negative.

***History of past illness***

The patient had no special history of past illness other than a hysterectomy procedure for fibroids 10 years prior.

***Personal and family history***

The patient had no special history of past illness other than a hysterectomy procedure for fibroids 10 years prior.

***Physical examination***

Neurological and pulmonary examination of the patient showed no obvious abnormalities.

***Laboratory examinations***

Lumbar puncture showed an increased intracranial pressure (> 330 mmH2O) without positive cytology and biochemical examination findings in CSF. However, further CSF ctDNA detection by next-generation sequencing showed an EGFR-Thr790Met mutation, and the variation frequency was 11.7%.

***Imaging examinations***

(1) Chest CT image at admission shows a lesion in the lingual segment of the upper lobe of the left lung (arrows); and (2) A follow-up cerebral contrast-enhanced MRI shows diffuse and linear enhancement along the surface of the cerebrum (arrows).

**FINAL DIAGNOSIS**

Based on these findings, a diagnosis of LM carcinomatosis of EGFR-Thr790Met-positive lung adenocarcinoma (cT3N3M1b: stage IVA) was established.

**TREATMENT**

Neither surgery nor chemotherapy was applied to the patient due to osseous metastasis. In addition, surgery could not achieve a radical cure. Hence, osimertinib (80  mg/d) was given as a second-line treatment.

**OUTCOME AND FOLLOW-UP**

The patient showed a good response within a month. What’s more, the patient’s headache and symptoms of intracranial hypertension disappeared rapidly after 3 days of osimertinib treatment. After discharge, osimertinib (80 mg/d) was continued, and the patient was closely followed-up. There were no obvious toxic or adverse side effects except for diarrhea and leukopenia. The lung lesion continued to shrink by the 6-month follow-up CT, and the intracranial pressure returned to normal without the patient experiencing a headache.

**DISCUSSION**

Patients with NSCLC and LM carcinoma have a poor prognosis. Early diagnosis and an appropriate treatment regimen are important to improve the prognosis. The analysis of ctDNA in CSF can be used to detect nervous system tumors and their drug resistance mechanism[8]. According to previous studies, EGFR-TKIs are effective in patients diagnosed with NSCLC and LM carcinoma with positive EGFR mutations[9]. Osimertinib has been reported to be more effective due to its better blood-brain barrier permeability[7]. This report shows a great clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in their CSF. Interestingly, the cytology in CSF and neuroimaging were all negative at the beginning, and when the patient's imaging turned positive, the result of CSF cytology examination was still negative one month after the EGFR-Thr790Met mutation was detected in CSF. Hence, we propose that the positive findings of CSF ctDNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging findings and the CSF findings and could thus be more helpful for therapy. Moreover, the character of this report is that headache is the chief complaint of the patient with lung cancer. The patient's initial outpatient cranial MRI and lumbar puncture showed no abnormalities in CSF biochemistry and cytology, except for elevated intracranial pressure. The patient's lung lesion was found due to the routine screening of chest CT with novel coronavirus. Just as the old saying goes, 'there is no great loss without some small gain'.

**CONCLUSION**

This report shows a great clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in CSF and proposes that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging findings, and the CSF findings and could thus be helpful for therapy. Moreover, the routine screening of chest CT with the novel coronavirus may provide unexpected results.

**REFERENCES**

1 **Mok TS,** Wu Y-L, Ahn M-J, et al Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med* 2017; **376**: 629-640 [PMID: 27959700 DOI: 10.1056/NEJMoa1612674]

2 **Umemura S**, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, Yamane H, Kamei H, Kiura K, Tanimoto M. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. *Lung Cancer* 2012; **77**: 134-139 [PMID: 22487432 DOI: 10.1016/j.lungcan.2012.03.002]

3 **De Mattos-Arruda L**, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nat Commun* 2015; **6**: 8839 [PMID: 26554728 DOI: 10.1038/ncomms9839]

4 **Zhao Y**, He JY, Zou YL, Guo XS, Cui JZ, Guo L, Bu H. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis. *BMC Neurol* 2019; **19**: 331 [PMID: 31856745 DOI: 10.1186/s12883-019-1554-5]

5 **De Mattos-Arruda L**, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. *Ann Oncol* 2014; **25**: 1729-1735 [PMID: 25009010 DOI: 10.1093/annonc/mdx804]

6 **Cheng H**, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. *Lancet Oncol* 2018; **19**: e43-e55 [PMID: 29304362 DOI: 10.1016/S1470-2045(17)30689-7]

7 **Yang JCH**, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. *J Clin Oncol* 2020; **38**: 538-547 [PMID: 31809241 DOI: 10.1200/JCO.19.00457]

8 **Zavodna M**, Bagshaw A, Brauning R, Gemmell NJ. The accuracy, feasibility and challenges of sequencing short tandem repeats using next-generation sequencing platforms. *PLoS One* 2014; **9**: e113862 [PMID: 25436869 DOI: 10.1371/journal.pone.0113862]

9 **Saboundji K**, Auliac JB, Pérol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaïd C. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. *Target Oncol* 2018; **13**: 501-507 [PMID: 30039345 DOI: 10.1007/s11523-018-0581-2]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images in October 20, 2021.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 11, 2022

**First decision:** May 30, 2022

**Article in press:** June 21, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E, E

**P-Reviewer:** Abdalla AN, Saudi Arabia; Kung WM, Taiwan; Sugimura H, Japan **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL.

**Figure Legends**



**Figure 1 Chest computed tomography.** A: Chest computed tomography image at admission shows a lesion in the lingual segment of the upper lobe of the left lung (arrows); B: A follow-up cerebral contrast-enhanced magnetic resonance imaging shows diffuse and linear enhancement along the surface of the cerebrum (arrows).



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**